AtriCure Inc (NAS:ATRC)
$ 23.76 2.565 (12.1%) Market Cap: 1.15 Bil Enterprise Value: 1.12 Bil PE Ratio: 0 PB Ratio: 2.52 GF Score: 66/100

AtriCure Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 05:30PM GMT
Release Date Price: $46.4 (-1.94%)
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

Good afternoon. Thank you for joining us for the second day of the Morgan Stanley Healthcare Conference. I'm Cecilia Furlong, medical device analyst here at Morgan Stanley. It's my pleasure to have AtriCure with us, CEO, Mike Carrel. Thank you, again, for being here with us.

Michael H. Carrel
AtriCure, Inc. - CEO, President & Director

Great to be here. Thanks for having us.

Questions & Answers

Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst

And really quickly, disclosures, see www.morganstanley.com/disclosures. But with that, I wanted to start with the macro, what you've seen in terms of staffing, other dynamics in your business. And then could you speak to I think we've had some questions in terms of CONVERGE specifically, and I want to spend some time on that. But what have been the biggest challenges as you think about just bringing this procedure up during COVID? There are a lot of logistical challenges

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot